TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06655883: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Suvorexant for the Treatment of Insomnia in Participants With Opioid Use Disorder

Sponsor: Merck Sharp & Dohme LLC · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 300 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$11,503,136

Rescue Site Savings

+$7,590,184

Unlock Full NCT06655883 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06655883 Rescue Dossier →